Author + information
There is an on-going debate about the best drug-eluting stent (DES) for patients with Diabetes Mellitus (DM). To date, there are no comparisons between everolimus-eluting stents (EES) and resolute zotarolimus-eluting stents (R-ZES) in patients with DM and MVD. The objective was to compare the safety and efficacy of EES vs R-ZES in patients with DM and MVD in the real-world practice.
Nationwide registry of consecutive patients with DM and MVD. The primary endpoint was target lesion failure (the combined of cardiac death, target vessel myocardial infarction, stent thrombosis or target lesion revascularization). Cox models (Fine and Gray) as well as propensity score matching were performed to adjust for significant covariates.
1981 lesions were included (1,302 EES, 679 R-ZES). Adjusted analysis showed no differences between stents in TLR (HR 0.629, 95%CI 0.359 to 1.10, p = 0.10) or TLF (HR 0.940 95%CI 0.88 to 1.01, p = 0.084). Propensity score matching confirmed no differences between stents (p=0.31).
In this nationwide registry, both EES and R-ZES provided comparable results. A large randomized clinical trial is warranted to find out the optimal DES in this high risk population.